Chiasma is a biopharmaceutical company that leverages innovative technology to convert injectable drugs into oral treatments for enhanced absorption and new indications. Founded in 2001, the company's focus lies in employing its unique Transient Permeability Enhancer (TPE) technology on approved drugs, facilitating their transition from injectable to oral forms. This has the potential to open up new uses or improve absorption rates.
Chiasma's TPE technology plays a crucial role in aiding the delivery of drugs to the gastrointestinal wall and subsequently to the liver. This breakthrough is especially significant for macromolecules that are presently limited to injection administration. Furthermore, TPE can also be applied to small molecules that are already orally available but suffer from poor absorption rates.
The company has attracted $70.00M in post-IPO equity investment as of 01 July 2020. This latest investment underscores the confidence in Chiasma's innovative approach and potential impact on the biopharma, biotechnology, health, and wellness industries.
